跳至主要内容
临床试验/NCT00429377
NCT00429377已完成3 期

Phase 3 Study of Tacrolimus(FK506)for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study

Astellas Pharma Inc7 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2003年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
64
试验地点
7
主要终点
Change of Lupus Nephritis - Disease Activity Index total score

研究概览

简要总结

This study consists of a 28-week placebo-controlled double-blind inter-group efficacy study in steroid refractory Lupus Nephritis patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
16 Years 至 64 Years(Child, Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Steroid refractory lupus nephritis
  • •more than 10mg of steroid failed to control disease activity
  • •patients who failed to reduce the amount of steroid
  • •patients who couldn't increase the amount of steroid due to side effects

排除标准

  • •Patients who started the immunosuppressant therapy or increased the amount of immunosuppressant within 12 weeks prior to test drug administration
  • •Patients who received cyclophosphamide puls within 24 weeks prior to test drug administration
  • •CNS( Central Nerve System) Lupus patients
  • •hepatic failure patients
  • •Serum creatinine ≧1.5mg/dL

研究组 & 干预措施

未命名试验

干预措施: tacrolimus (Drug)

结局指标

主要结局

Change of Lupus Nephritis - Disease Activity Index total score

次要结局

  • proteinuria, RBC-urine, serum creatinine, anti ds-DNA antibody, complement (C3)

研究者

申办方类型
Industry

研究点 (7)

Loading locations...

相似试验